Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) – Leerink Swann issued their Q2 2017 earnings per share (EPS) estimates for Jazz Pharmaceuticals PLC in a report issued on Tuesday. Leerink Swann analyst J. Gerberry expects that the brokerage will post earnings of $2.84 per share for the quarter. Leerink Swann currently has a “Buy” rating and a $182.00 price target on the stock. Leerink Swann also issued estimates for Jazz Pharmaceuticals PLC’s Q3 2017 earnings at $2.47 EPS, Q4 2017 earnings at $2.78 EPS, FY2018 earnings at $11.87 EPS and FY2019 earnings at $14.64 EPS.

A number of other equities analysts have also recently commented on the company. Deutsche Bank AG restated a “buy” rating and set a $158.00 target price (up from $155.00) on shares of Jazz Pharmaceuticals PLC in a report on Thursday, August 11th. Barclays PLC restated a “buy” rating and set a $200.00 target price on shares of Jazz Pharmaceuticals PLC in a report on Wednesday, August 10th. Mizuho lowered their target price on Jazz Pharmaceuticals PLC from $195.00 to $185.00 and set a “buy” rating for the company in a report on Wednesday, August 10th. Goldman Sachs Group Inc. restated a “buy” rating and set a $195.00 target price (down from $196.00) on shares of Jazz Pharmaceuticals PLC in a report on Thursday, August 11th. Finally, BMO Capital Markets lowered their target price on Jazz Pharmaceuticals PLC from $195.00 to $192.00 and set an “outperform” rating for the company in a report on Wednesday. Four equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $178.25.

Earnings History and Estimates for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) opened at 113.11 on Friday. The stock’s 50 day moving average price is $117.73 and its 200-day moving average price is $135.43. The stock has a market cap of $6.84 billion, a price-to-earnings ratio of 19.78 and a beta of 1.35. Jazz Pharmaceuticals PLC has a 52 week low of $95.80 and a 52 week high of $160.00.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) last issued its quarterly earnings results on Tuesday, November 8th. The specialty pharmaceutical company reported $2.57 earnings per share for the quarter, missing the Zacks’ consensus estimate of $2.61 by $0.04. Jazz Pharmaceuticals PLC had a return on equity of 30.50% and a net margin of 24.81%. The business had revenue of $374 million for the quarter, compared to analysts’ expectations of $389.34 million. During the same quarter in the previous year, the firm posted $2.52 EPS. Jazz Pharmaceuticals PLC’s revenue was up 9.8% on a year-over-year basis.

In related news, SVP Michael Patrick Miller sold 200 shares of the firm’s stock in a transaction that occurred on Monday, September 19th. The stock was sold at an average price of $126.17, for a total transaction of $25,234.00. Following the transaction, the senior vice president now owns 17,325 shares in the company, valued at approximately $2,185,895.25. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Seamus Mulligan sold 27,968 shares of the firm’s stock in a transaction that occurred on Thursday, August 25th. The stock was sold at an average price of $128.32, for a total value of $3,588,853.76. Following the transaction, the director now owns 1,072,411 shares in the company, valued at approximately $137,611,779.52. The disclosure for this sale can be found here. Corporate insiders own 3.90% of the company’s stock.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in JAZZ. Cadian Capital Management LP increased its position in Jazz Pharmaceuticals PLC by 71.6% in the third quarter. Cadian Capital Management LP now owns 1,311,292 shares of the specialty pharmaceutical company’s stock worth $159,296,000 after buying an additional 547,056 shares in the last quarter. Fiera Capital Corp bought a new position in shares of Jazz Pharmaceuticals PLC during the second quarter valued at $46,955,000. Victory Capital Management Inc. increased its position in shares of Jazz Pharmaceuticals PLC by 35,390.5% in the third quarter. Victory Capital Management Inc. now owns 303,444 shares of the specialty pharmaceutical company’s stock valued at $36,863,000 after buying an additional 302,589 shares during the period. Renaissance Technologies LLC increased its position in shares of Jazz Pharmaceuticals PLC by 1,044.1% in the first quarter. Renaissance Technologies LLC now owns 215,100 shares of the specialty pharmaceutical company’s stock valued at $28,081,000 after buying an additional 196,300 shares during the period. Finally, Polar Capital LLP bought a new position in shares of Jazz Pharmaceuticals PLC during the second quarter valued at $25,560,000. Hedge funds and other institutional investors own 88.35% of the company’s stock.

Jazz Pharmaceuticals PLC Company Profile

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

5 Day Chart for NASDAQ:JAZZ

Receive News & Stock Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related stocks with our FREE daily email newsletter.